

Vol. 7, No. 23 2 December 1997

ISSN 0960-894X

W1 B1876KE
NO. 23 1997
-----SEQ: SR0069668
BIOORGANIC AND MEDICINAL
CHEMISTRY LETTERS 01/08/98

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication
for Rapid Dissemination of
Preliminary Communications on all aspects of
Bioorganic Chemistry, Medicinal Chemistry,
Bioinorganic Chemistry and related disciplines

Editor-in-Chief

DALE L BOGER

The Scripps Research Institute
La Jolla
CA 92037
USA


Chairman of the Executive
Board of Editors for
Tetrahedron Publications

SIR DEREK BARTON


Texas A & M University
USA



PERGAMON



PROPERTY OF THE
**NATIONAL
LIBRARY OF
MEDIC**



Columbia Exhibit 2111
Illumina, Inc. v. The Trustees
of Columbia University in the
City of New York
IPR2018-00291, 318, 322, 385 & 797

Vol. 7, No. 23 2 December 1997

ISSN 0960-894X

W1 B1876KE
NO. 23 1997
-----SEQ: SR0069668
BIOORGANIC AND MEDICINAL
CHEMISTRY LETTERS 01/08/98

Bioorganic & Medicinal Chemistry Letters

A Tetrahedron Publication
for Rapid Dissemination of
Preliminary Communications on all aspects of
Bioorganic Chemistry, Medicinal Chemistry,
Bioinorganic Chemistry and related disciplines

Editor-in-Chief

DALE L BOGER

*The Scripps Research Institute
La Jolla
CA 92037
USA*

Chairman of the Executive
Board of Editors for
Tetrahedron Publications

SIR DEREK BARTON


*Texas A & M University
USA*



PERGAMON



PROPERTY OF THE
**NATIONAL
LIBRARY OF
MEDICINE**



BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

Editor-in-Chief: PROFESSOR D. L. BOGER

Managing Editor: A. Crown

Department of Chemistry, The Scripps Research Institute, 10550 North Torrey Pines Road

La Jolla, California 92037, USA

Fax: (1) 619 784 7550

[Fax: (800) 410 1557 toll-free from USA and Canada]

European Regional Editor: Professor L. Ghosez, Laboratoire de Chimie Organique de Synthèse, Université Catholique de Louvain, B-1348 Louvain-la-Neuve, Belgium

Fax: (32) 10 47 29 44

Japanese Regional Editor: Professor M. Shibasaki, Faculty of Pharmaceutical Sciences, University of Tokyo, 7-3-1 Hongo, Bunkyo-ku,

Tokyo 113, Japan

Fax: (81) 3 5684 5206

EXECUTIVE BOARD OF EDITORS FOR TETRAHEDRON PUBLICATIONS

Chairman: Professor Sir Derek Barton, FRS, Department of Chemistry, Texas A & M University, College Station, Texas 77843-3255, USA

Professor Sir J. E. Baldwin, FRS, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor S. G. Davies, Dyson Perrins Laboratory, Oxford, OX1 3QY, UK

Professor A. R. Katritzky, FRS, Department of Chemistry, University of Florida, Gainesville, FL 32611, USA

Professor N. K. Kochetkov, N. D. Zelinsky Institute of Organic Chemistry, Academy of Sciences, Moscow B-334, Russia

Professor Lin Guo-Qiang, Shanghai Institute of Organic Chemistry, Academia Sinica, Shanghai 200032, China

Professor S. F. Martin, Department of Chemistry and Biochemistry, University of Texas, Austin, TX 78712, USA

Professor A. McKillop, University of East Anglia, School of Chemical Sciences, University Plain, Norwich, NR4 7TJ, UK

Professor W. B. Motherwell, Department of Chemistry, University College, 20 Gordon Street, London WC1H 0AJ, UK

Professor G. Ourisson, Centre National de la Recherche Scientifique, Centre de Neurochimie, 67084 Strasbourg, Cedex, France

(Associate Editor, Professor G. Solladié)

Professor G. H. Posner, Department of Chemistry, Johns Hopkins University, Baltimore, MD 21218, USA

Professor T. Shioiri, Faculty of Pharmaceutical Sciences, Nagoya City University, Tanabe-dori, Mizuho-ku, Nagoya 467, Japan

Professor W. Steglich, Institut für Organische Chemie der Universität München, Karlstr. 23, D-80333 München, Germany

Professor H. H. Wasserman, Department of Chemistry, Yale University, PO Box 208107, New Haven, CT 06520-8107, USA

(Associate Editor, Professor D. P. Curran)

Professor C.-H. Wong, Department of Chemistry, The Scripps Research Institute, La Jolla, CA 92037, USA

Professor Y. Yamamoto, Department of Chemistry, Faculty of Science, Tohoku University, Sendai 980-77, Japan

(Associate Editor, Professor M. Hirama)

BOARD OF CONSULTING EDITORS

R. Abeles, Waltham, MA
P. S. Anderson, Lansdale, PA
J. K. Barton, Pasadena, CA
S. J. Benkovic, Pennsylvania, PA
R. C. Breslow, New York, NY
J. A. Bristol, Ann Arbor, MI
T. C. Bruice, Santa Barbara, CA
A. R. Chamberlin, Irvine, CA
J. P. Collman, Stanford, CA
P. N. Confalone, Wilmington, DE
E. J. Corey, Cambridge, MA
S. J. Danishefsky, New York, NY
P. B. Dervan, Pasadena, CA
A. Eschenmoser, Zürich
J.-M. Fang, Taipei
A. R. Fersht, Cambridge

D. M. Floyd, Princeton, NJ
A. K. Ganguly, Bloomfield, NJ
D. Gani, St Andrews
B. Giese, Basel
H. B. Gray, Pasadena, CA
J. T. Groves, Princeton, NJ
G. L. Grunewald, Lawrence, KS
P. Herrling, Basel
D. Hilvert, La Jolla, CA
R. H. Holm, Cambridge, MA
D. C. Horwell, Cambridge
B. Imperiali, Pasadena, CA
K. Janda, La Jolla, CA
W. L. Jorgensen, New Haven, CT
D. D. Kelth, Nutley, NJ
P. Krogsgaard-Larsen, Copenhagen

R. A. Lerner, La Jolla, CA
S. J. Lippard, Cambridge, MA
D. Mansuy, Paris
B. W. Metcalf, King of Prussia, PA
L. A. Mitscher, Lawrence, KS
W. H. Moos, Emeryville, CA
K. Mori, Tokyo
K. Nakanishi, New York, NY
K. C. Nicolaou, La Jolla, CA
T. Ogawa, Saitama
M. Ohno, Tokyo
H. L. Pearce, Indianapolis, IN
P. Potler, Gif-sur-Yvette
C. D. Poulter, Salt Lake City, UT
J. Rebek, Jr, Cambridge, MA
B. Samuelsson, Stockholm

R. L. Schowen, Lawrence, KS
S. L. Schreiber, Cambridge, MA
P. G. Schultz, Berkeley, CA
A. I. Scott, College Station, TX
I. Shinkai, Rahway, NJ
C. J. Sih, Madison, WI
J. Stubbe, Cambridge, MA
N. K. Terrett, Sandwich
G. L. Verdine, Cambridge, MA
H. Waldmann, Karlsruhe
C. T. Walsh, Boston, MA
G. Whitesides, Cambridge, MA
R. V. Wolfenden, Chapel Hill, NC

PUBLISHED TWICE MONTHLY

Subscription Rates

Annual Institutional Subscription Rates 1998: Europe, The CIS and Japan 2752.00 NLG. All other countries US\$1582.00. NLG prices exclude VAT. Non-VAT registered customers in the European Community will be charged the appropriate VAT in addition to the price listed. Prices include postage and insurance and are subject to change without notice. Any enquiry relating to subscriptions should be sent to: **The Americas:** Elsevier Science, Customer Support Department, PO Box 945, New York, NY 10010, USA [Tel: (+1) 212-633-3730/1-888 4ES-INFO. Fax: (+1) 212-633-3680. E-mail: usinfo-f@elsevier.com].

Japan: Elsevier Science, Customer Support Department, 9-15 Higashi-Azabu 1-chome, Minato-ku, Tokyo 106, Japan [Tel: (+81) 3-5561-5033. Fax: (+81) 3-5561-5047. E-mail: kyf04035@niftyserve.or.jp].

Asia Pacific (excluding Japan): Elsevier Science (Singapore) Pte Ltd, No. 1 Temasek Avenue, 17-01 Millenia Tower, Singapore 039192. [Tel: (+65) 434-3727. Fax: (+65) 337-2230. E-mail: asiainfo@elsevier.com.sg].

Rest of the World: Elsevier Science Customer Service Department, PO Box 211, 1001 AE Amsterdam, The Netherlands [Tel: (+31) 20-485-3757. Fax: (+31) 20-485-3432. E-mail: nlinfo-f@elsevier.nl].

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS

A Tetrahedron Publication for Rapid Dissemination of Preliminary
Communications on all Aspects of Bioorganic Chemistry, Medicinal Chemistry,
Bioinorganic Chemistry and Related Disciplines

Editor-in Chief

Professor D. L. Boger

Chairman of the Executive Board of Editors for Tetrahedron Publications

Professor Sir Derek Barton, FRS



PERGAMON



ACYCLIC NUCLEOSIDE TRIPHOSPHATE ANALOGS AS TERMINATORS IN BIOCATALYTIC DNA REPLICATION


Carlos I. Martinez,^a M. Ali Ansari,^b Richard Gibbs,^b and Kevin Burgess^{*a}

^aDepartment of Chemistry, Texas A & M University, College Station, TX 77843-3255, U.S.A.


^bDepartment of Molecular and Human Genetics, Baylor College of Medicine,
One Baylor Plaza, Houston, TX 77030, U.S.A.

Abstract: The acyclic nucleoside triphosphates **1** and **2** were prepared and tested as substrates for several DNA replicating enzymes; AmpliTaq[®] FS and Taqenase[®] accepted these compounds as substrates leading to chain termination. © 1997 Elsevier Science Ltd.


Terminators of enzyme-directed DNA synthesis are central to the Sanger-based methods for DNA sequencing¹ used in The Human Genome Project and most other projects involving unraveling of DNA codes. It therefore surprising that the terminators still used are exactly those originally introduced. The human genome is approximately 3×10^9 bases hence the cost of the terminators becomes an important issue. A 1 cent saving per base is equivalent to \$30 million dollars for the whole genome sequence. Attempts to find cheaper alternatives to the 2',3'-dideoxyribonucleoside-5'-triphosphates (ddNTPs) that are generally used as chain terminators therefore are timely.² The extensive literature on peptide nucleic acids (PNAs)³ indicates that the ribose framework of ddNTPs is not essential for high binding affinity and specificity. We therefore supposed that triphosphates like **1** and **2** might be effective terminators for biocatalytic DNA replication. This communication reports syntheses of compounds **1** and **2**, and gel assays to test their efficacy as ddNTP surrogates.



Compound **1** was formed by coupling the known⁴ thymidine acetate **3** with *N*-methylethanolamine as indicated below. Triphosphorylation of alcohol **4** using the conditions described by Eckstein and coworkers⁵ proceeded to give the triphosphate **1** more efficiently than triphosphorylation of many other substrates that we have attempted. Thus, HPLC, ³¹P NMR, and MALDI-MS analyses of the material recovered after ion exchange column chromatography indicated that it was predominantly triphosphate. A small sample of this material was purified by RP-HPLC for use in the experiments with DNA polymerases.



A slightly different approach was used to prepare the adenine derivative **2** (i.e., the bromoacetate intermediate **5** was prepared first) then coupled with adenine. Desilylation and triphosphorylation reactions were then used to complete the synthesis. This approach is more divergent than the synthesis of compound **1** insofar as many different base analogs could be prepared from bromoacetate **5**. In this particular case, the coupling of **5** to the heterocycle gave low yields under the conditions indicated. This yield was not improved when another base (K_2CO_3) and solvent (DMSO) were used. A possible explanation for these inefficient reactions is that competing reactions at the exocyclic amine of adenine may have occurred. RP-HPLC, ^{31}P NMR, and MALDI MS after ion exchange chromatography indicated the efficiency of the phosphorylation.



The gel assay used to test for incorporation of compounds **1** and **2** was adapted from that previously reported from these laboratories.⁶ Thus a short synthetic template having the sequence 3'-ACATTTTGCTGCCGGTCAGGTGGAGGC was primed with a 5'- ^{32}P -labeled primer with the sequence 3'-ACATTTTGCTGCCGGTCA. The double-strand DNA so produced was subjected to biocatalytic replication

using reaction mixtures containing either the thymidine analog **1** and dATP and dCTP, or the adenosine analog **2** and dCTP. Chain termination was characterized by comparison with control lanes using ddTTP and ddATP.⁷

The following DNA polymerases were tested in the assay outlined above: *rTth* DNA Pol (Perkin-Elmer), HIV-1 RT, AmpliTaq[®] DNA Pol (Perkin Elmer), Taqenase[®] (ScienTech), AmpliTaq[®] FS DNA Pol (Perkin-Elmer), and *Bst* DNA Pol (Bio-Rad). The results demonstrated that incorporation/termination was observed for both analogs when AmpliTaq[®] FS and Taqenase[®] were used (Table 1). At a concentration of 100 μ M, the adenosine analog **2** was incorporated by both enzymes, whereas a 1 mM concentration of **1** caused only partial termination under similar conditions (Figure 1). The adenine derivative *N*-MeA **2** was therefore incorporated more efficiently than the thymidine counterpart **1**.

The mutants Taqenase[®] and AmpliTaq[®] FS are known to have a relatively broad spectrum of substrate tolerance⁸ so it was unsurprising that these two enzymes should show the desired activities whereas several others did not. In fact, amongst the wild type enzymes, only HIV-1 RT gave incorporation/termination, and in that case, substrate concentrations of 1 mM were required for both **1** and **2**.




Figure 1. Incorporation of *N*-MeT **1** and of *N*-MeA **2** by AmpliTaq FS. All dNTPs were used at a concentration of 0.1 μ M and ddNTPs at 0.5 μ M. Substrates used in the control lanes 1–6 were as follows: lane 1 contains no ddNTPs or dNTPs; lane 2 dCTP; lane 3 dCTP and ddATP; lane 4 dCTP and dATP; lane 5 dCTP, dATP and ddTTP; lane 6 dCTP, dATP, dTTP and ddGTP. Lanes 7–12 and lanes 13–17 featured progressively greater concentrations of triphosphates **1** and **2** in combination with dCTP (lanes 7–12) or dCTP and dATP (lanes 13–17), respectively (Table 1). Note 7 gives further details.

using reaction mixtures containing either the thymidine analog **1** and dATP and dCTP, or the adenosine analog **2** and dCTP. Chain termination was characterized by comparison with control lanes using ddTTP and ddATP.⁷

The following DNA polymerases were tested in the assay outlined above: *rTth* DNA Pol (Perkin-Elmer), HIV-1 RT, AmpliTaq[®] DNA Pol (Perkin Elmer), Taqenase[®] (ScienTech), AmpliTaq[®] FS DNA Pol (Perkin-Elmer), and *Bst* DNA Pol (Bio-Rad). The results demonstrated that incorporation/termination was observed for both analogs when AmpliTaq[®] FS and Taqenase[®] were used (Table 1). At a concentration of 100 μ M, the adenosine analog **2** was incorporated by both enzymes, whereas a 1 mM concentration of **1** caused only partial termination under similar conditions (Figure 1). The adenine derivative *N*-MeA **2** was therefore incorporated more efficiently than the thymidine counterpart **1**.

The mutants Taqenase[®] and AmpliTaq[®] FS are known to have a relatively broad spectrum of substrate tolerance⁸ so it was unsurprising that these two enzymes should show the desired activities whereas several others did not. In fact, amongst the wild type enzymes, only HIV-1 RT gave incorporation/termination, and in that case, substrate concentrations of 1 mM were required for both **1** and **2**.




Figure 1. Incorporation of *N*-MeT **1** and of *N*-MeA **2** by AmpliTaq FS. All dNTPs were used at a concentration of 0.1 μ M and ddNTPs at 0.5 μ M. Substrates used in the control lanes 1–6 were as follows: lane 1 contains no ddNTPs or dNTPs; lane 2 dCTP; lane 3 dCTP and ddATP; lane 4 dCTP and dATP; lane 5 dCTP, dATP and ddTTP; lane 6 dCTP, dATP, dTTP and ddGTP. Lanes 7–12 and lanes 13–17 featured progressively greater concentrations of triphosphates **1** and **2** in combination with dCTP (lanes 7–12) or dCTP and dATP (lanes 13–17), respectively (Table 1). Note 7 gives further details.

Table 1. Termination assays for *N*-MeA **1** and *N*-MeT **2**.

enzymes	<i>N</i> -MeT 1	<i>N</i> -MeA 2
<i>rTth</i> DNA Polymerase	no incorporation ^a	no incorporation
HIV-1 RT	termination (1 mM) ^b	termination (1 mM)
AmpliTaq [®] DNA Pol.	no incorporation	-- ^c
Taqenase [®]	termination (1 mM)	termination (100 μ M)
AmpliTaq [®] FS	termination (1 mM)	termination (100 μ M)
<i>Bst</i> DNA Polymerase	no incorporation	no incorporation

^aNo incorporation observed. ^bFull termination observed at the concentration in parenthesis. ^cNot assayed.

In conclusion, the thymidine and adenosine analogs **1** and **2** are substrates for some DNA replicating enzymes with high tolerance for variation in substrate structure. They can be incorporated to give near complete termination of enzymatic extension of a short DNA-template. For the *N*-MeA analog **2**, concentrations as low as 100 μ M were sufficient, whereas for *N*-MeT **1** termination only occurred when millimolar concentrations of were used. Analogs **1** and **2** are incorporated less readily than ddTTP and ddATP and they are not practical substitutes under the conditions described here. They are, however, easily prepared via facile triphosphorylation reactions, and may be incorporated more efficiently under other conditions.

Acknowledgments. We thank Dr. Mike Metzker for very helpful discussions, and Mr. Alex J. Zhang for MALDI-MS determinations. Financial support was provided by The Texas Advanced Technology Program and The Robert A. Welch Foundation, and K.B. thanks the NIH for a Research Career Development Award and the Alfred P. Sloan Foundation. NMR facilities were provided by the NSF instrumentation program.

References and Notes

1. Sanger, F.; Nicklen, S.; Coulson, A. R. *Proc. Natl. Acad. Sci. U.S.A.* **1977**, *74*, 5463.
2. Hobbs, F. W.; Cocuzza, A. J., European, 1988, 87305844.0.
3. Hyrup, B.; Nielsen, P. E. *Bioorg. Med. Chem.* **1996**, *4*, 5.
4. Kosynkina, L.; Wang, W.; Liang, T. C. *Tetrahedron Lett.* **1994**, *35*, 5173.
5. Ludwig, J.; Eckstein, F. *J. Org. Chem.* **1989**, *54*, 631.
6. Metzker, M. L.; Raghavachari, R.; Richards, S.; Jacutin, S. E.; Civitello, A.; Burgess, K.; Gibbs, R. A. *Nucl. Acids Res.* **1994**, *22*, 4259.
7. For three of the enzymes (HIV-1 RT, AmpliTaq[®] FS, and Taquenase[®]) it was necessary to determine the minimum concentrations of dNTPs for efficient incorporation without misincorporation (i.e., mismatch formation), then repeat the procedure to ascertain the ddNTP concentrations. The protocol for these experiments has been published.⁶ These concentrations were determined to be: 0.5 μ M dNTPs and 0.05 μ M ddNTPs for HIV-1 RT; 0.1 μ M dNTPs and 0.5 μ M for AmpliTaq[®] FS and Taquenase[®]. Optimal assay concentrations/conditions for *Bst* and *rTth* DNA polymerases were those as reported previously.⁶ Details of the assay were as follows. The synthetic template was primed with the 5'-³²P-labeled primer, melted at 80 °C, then allowed to anneal by slow cooling to room temperature. The double-strand DNA so produced was mixed with the analog (**1** or **2**) and the various dNTP and ddNTP's at the concentrations given above. After incubation for 15 min at the temperature prescribed for each enzyme, the reactions were quenched by addition of 5 μ L of stop solution containing 98% diisopropyl formamide, 10 mM EDTA, pH 8.0, 0.025% bromophenol blue, 0.025% xylene cyanol. The samples were heated to 85 °C for 5 min, chilled in ice, and 3 μ L were loaded into 20% acrylamide gels. Following electrophoresis the gel was fixed in aqueous 10% acetic acid, 10% methanolic solution (v/v), dried, and autoradiographed on Hyperfilm TM-MP (Amersham).
8. Tabor, S.; Richardson, C. C. *Proc. Natl. Acad. Sci. U.S.A.* **1995**, *92*, 6339.

(Received in USA 1 August 1997; accepted 20 October 1997)